Roche and reMYND have entered into a partnership to develop novel therapeutics that can slow down neurodegeneration in Parkinson's and Alzheimer's patients.
The partnership will focus on two of reMYND's compounds, which work by inhibiting a-synuclein neurotoxicity in Parkinson's disease and tau neurotoxicity in Alzheimer's disease.
Roche will be responsible for lead-optimisation, pre-clinical development and input into chemistry, while reMYND will continue to conduct non-clinical pharmacology studies and examine the underlying molecular mechanisms further.
Under the agreement, reMYND could receive up to €500m in the form of milestone payments, additional FTE payments and royalties based on resulting net sales.
Roche will conduct the clinical development and will hold the license for worldwide commercialisation.